These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28608116)

  • 1. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
    Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
    Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
    Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
    Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
    Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.
    Tanahashi T; Yoshida K; Yamaguchi K; Okumura N; Takeno A; Fujitani K; Fukushima N; Takiguchi N; Nishida Y; Boku N; Yoshikawa T; Terashima M
    Gastric Cancer; 2019 Jan; 22(1):130-137. PubMed ID: 29799059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
    Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
    Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2289-91. PubMed ID: 24394088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
    Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
    Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
    Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.
    Iizuka A; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    World J Surg; 2019 Aug; 43(8):2016-2024. PubMed ID: 30737551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.